Maria C Rosario

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc
    Maria C Rosario
    Department of Clinical PK PD, Pfizer Global Medical and Development Sciences, Eastern Point Road, Groton, CT 06340, USA
    Clin Pharmacol Ther 78:508-19. 2005
  2. ncbi request reprint A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc
    Maria C Rosario
    Department of Clinical Pharmacology, Pfizer Clinical R and D, Groton, CT 06340, USA
    J Acquir Immune Defic Syndr 42:183-91. 2006
  3. pmc Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients
    Maria C Rosario
    Department of Clinical Pharmacology, Pfizer Global R and D, Groton, CT, USA
    Br J Clin Pharmacol 65:86-94. 2008
  4. pmc Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers
    Samantha Abel
    Pfizer Global Research and Development, Sandwich, UK
    Br J Clin Pharmacol 65:5-18. 2008
  5. doi request reprint Four-factor structure of obsessive-compulsive disorder symptoms in children, adolescents, and adults
    S Evelyn Stewart
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Am Acad Child Adolesc Psychiatry 47:763-72. 2008

Collaborators

  • Philippe Jacqmin
  • Mike Westby
  • Daniel Geller
  • S Evelyn Stewart
  • Samantha Abel
  • Marion Leboyer
  • Nadia Chabane
  • Caroline E Ridgway
  • David L Pauls
  • Jeremiah M Scharf
  • Alice S Carter
  • Elna van der Ryst
  • Christine G Medhurst
  • Lilya Katsovich
  • James F Leckman
  • Richard Delorme
  • Steven Rasmussen
  • Timothy A Brown
  • Lee Baer
  • Denis Sukhodolsky
  • Gary J Muirhead
  • Wayne Goodman
  • Richard J Taylor-Worth
  • Michael A Jenike
  • Cornelia Illmann

Detail Information

Publications5

  1. ncbi request reprint A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc
    Maria C Rosario
    Department of Clinical PK PD, Pfizer Global Medical and Development Sciences, Eastern Point Road, Groton, CT 06340, USA
    Clin Pharmacol Ther 78:508-19. 2005
    ....
  2. ncbi request reprint A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc
    Maria C Rosario
    Department of Clinical Pharmacology, Pfizer Clinical R and D, Groton, CT 06340, USA
    J Acquir Immune Defic Syndr 42:183-91. 2006
    ....
  3. pmc Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients
    Maria C Rosario
    Department of Clinical Pharmacology, Pfizer Global R and D, Groton, CT, USA
    Br J Clin Pharmacol 65:86-94. 2008
    ....
  4. pmc Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers
    Samantha Abel
    Pfizer Global Research and Development, Sandwich, UK
    Br J Clin Pharmacol 65:5-18. 2008
    ..To evaluate the pharmacokinetics, safety and tolerability of single and multiple oral doses of maraviroc in healthy volunteers...
  5. doi request reprint Four-factor structure of obsessive-compulsive disorder symptoms in children, adolescents, and adults
    S Evelyn Stewart
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Am Acad Child Adolesc Psychiatry 47:763-72. 2008
    ..Identification of a category-based OCD symptom dimension structure that is validated for use across child, adolescent, and adult age groups is necessary to guide ongoing translational research...